Caplin Point Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 524742 | NSE: CAPLIPOINT | Pharmaceuticals & Drugs | Small Cap

Caplin Point Lab Share Price

2,421.70 -15.10 -0.62%
as on 13-Dec'24 14:36

DeciZen - make an informed investing decision on Caplin Point Lab

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Caplin Point Laboratories stock performance -

mw4me loader
P/E Ratio (CD):
37.53
Market Cap:
18,522.5 Cr.
52-wk low:
1,180
52-wk high:
2,486.7

Is Caplin Point Laboratories Ltd an attractive stock to invest in?

1. Is Caplin Point Laboratories Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Caplin Point Laboratories Ltd is a average quality company.

2. Is Caplin Point Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Caplin Point Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Caplin Point Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Caplin Point Laboratories Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Caplin Point Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Caplin Point Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 71.1%55.4%69%64.1%45.6%33.4%28.8%28.8%26.9%26.9%-
Value Creation
Index
4.13.03.93.62.31.41.11.11.01.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 2523184025406498631,0611,2691,4671,6941,831
Sales YoY Gr.-26.4%26.2%34.4%20.2%33.1%23%19.6%15.5%15.5%-
Adj EPS 5.78.412.418.622.325.932.438.648.559.264.9
YoY Gr.-48.5%46.9%50.2%20%16.1%25.2%18.9%25.7%22.1%-
BVPS (₹) 11.821.729.747.778114.2144.9183.9235.9293.2334.5
Adj Net
Profit
42.963.693.5141169196245292367449493
Cash Flow from Ops. 49.956.567.666.583.444.7269337271318-
Debt/CF from Ops. 00.10000.80.1000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 23.6%21.2%16.9%15.5%
Adj EPS 29.8%21.6%22.2%22.1%
BVPS42.9%30.3%26.5%24.3%
Share Price 40.1% 51.2% 44.9% 98.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Jun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
55.343.15347.733.824.82321.921.821.420.7
Op. Profit
Mgn %
24.828.131.236.235.730.13131.130.132.633
Net Profit
Mgn %
17.12023.3262622.72423.725.126.827
Debt to
Equity
00000000000
Working Cap
Days
47716795133176197211221225187
Cash Conv.
Cycle
-49-68-51-19331121159498115155

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.87%

Net Profit is growing at healthy rate in last 3 years 22.20%

Sales growth is good in last 4 quarters at 16.85%

Return on Equity has declined versus last 3 years average to 20.70%

Latest Financials - Caplin Point Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 39.9 64.9
TTM Sales (₹ Cr.) 666 1,831
BVPS (₹.) 201.9 334.5
Reserves (₹ Cr.) 1,520 2,527
P/BV 12.07 7.29
PE 61.01 37.53
From the Market
52 Week Low / High (₹) 1179.95 / 2486.65
All Time Low / High (₹) 0.18 / 2486.65
Market Cap (₹ Cr.) 18,523
Equity (₹ Cr.) 15.2
Face Value (₹) 2
Industry PE 44

Management X-Ray of Caplin Point Lab:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Caplin Point Lab

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSJun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales2522394025406498631,0611,2691,4671,694
Operating Expenses 1921752773454176037378751,0261,143
Manufacturing Costs25223848578386103117151
Material Costs136121185238289413472558663724
Employee Cost 181830384667102115136143
Other Costs 1414242125407799110125
Operating Profit 6064125195232260324395441551
Operating Profit Margin (%) 23.7%26.9%31.1%36.2%35.7%30.1%30.6%31.1%30.0%32.6%
Other Income 341013194128395767
Interest 1011102111
Depreciation 871319233237474553
Exceptional Items 0000000000
Profit Before Tax 5360121188227269314386451564
Tax 121425445054627774103
Profit After Tax 414696145177215251308377461
PAT Margin (%) 16.3%19.2%23.8%26.8%27.2%24.9%23.7%24.3%25.7%27.2%
Adjusted EPS (₹)5.46.112.719.223.328.432.039.649.660.2
Dividend Payout Ratio (%)18%20%12%10%9%9%9%10%9%8%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSJun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 931272253616269381,1711,4681,8652,301
Share Capital 15151515519090909090
Reserves 781112103455758491,0811,3791,7752,212
Minority Interest00000918262731
Debt1100000130
Long Term Debt1100000000
Short Term Debt0000000130
Trade Payables42567994606489156153209
Others Liabilities 93845445561148779130143
Total Liabilities 2292673585007431,1261,3641,7302,1772,686

Fixed Assets

Gross Block143181195232272355423446480702
Accumulated Depreciation303743624582117159201250
Net Fixed Assets113144152169227273305287280453
CWIP 31031510201418221117
Investments 00174770611189281376
Inventories1419222837238179227288363
Trade Receivables6833126160229279317394543
Cash Equivalents 45689379153223438463493553
Others Assets202737358682136329220282
Total Assets 2292673585007431,1261,3641,7302,1772,686

Cash Flow

(All Figures are in Crores.)
PARTICULARSJun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 504268668345269337271318
PBT 5360121188227269314386451564
Adjustment 649151972330122
Changes in Working Capital 2-5-38-100-120-177-22-104-139
Tax Paid -12-16-24-36-43-55-66-81-88-109
Cash Flow From Investing Activity -23-6-36-69-100-55-29-377-218-320
Capex -25-8-25-49-65-77-73-91-193-146
Net Investments 00-17-27-201024-200-49-93
Others 3267-151320-8525-81
Cash Flow From Financing Activity -9-14-7-129080-24-41-28-38
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -100000-19-1700
Interest Paid 000000-2-1-1-1
Dividend Paid -7-14-6-11-15-33-3-23-30-34
Others 00001051130-13-3
Net Cash Flow 192325-147370215-8126-40
PARTICULARSJun'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)55.7843.1354.9749.4337.1429.5825.6524.7723.6822.97
ROCE (%)71.1155.4169.0364.0845.5933.3528.8228.7726.8526.92
Asset Turnover Ratio1.230.961.281.261.040.920.850.820.750.7
PAT to CFO Conversion(x)1.220.910.710.460.470.211.071.090.720.69
Working Capital Days
Receivable Days41019548082878688101
Inventory Days17251917195872586470
Payable Days98147133132985559808591

Caplin Point Laboratories Ltd Stock News

Caplin Point Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Caplin Point Lab on 13-Dec-2024 14:36 is ₹2,421.7.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Dec-2024 14:36 the market cap of Caplin Point Lab stood at ₹18,522.5.
The latest P/E ratio of Caplin Point Lab as of 13-Dec-2024 14:36 is 61.01.
The latest P/B ratio of Caplin Point Lab as of 13-Dec-2024 14:36 is 12.07.
The 52-week high of Caplin Point Lab is ₹2,486.7 and the 52-week low is ₹1,180.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Caplin Point Lab is ₹665.8 ( Cr.) .

About Caplin Point Laboratories Ltd

Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.

The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.

Business area of the company

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.

Products

  • Liquid Injections
  • Lyophilised Injections
  • Opthalmic
  • Tablets
  • Liquid Orals
  • Capsule
  • Softgel Capsules
  • Suppositories & Ovules
  • Powder for Injection
  • Dry syrup
  • Topicals
  • Liquid Injections
  • Inhalers
  • Ophthalmic
  • IV Infusion
  • Lyophilised Products
  • Branded Products
  • Dermo Cosmetics

Awards and recognitions

  • 2014: Forbes Asia Best under a Billion Award - 2014.
  • 2015: Forbes Asia Best under a Billion Award - 2015.
  • 2016: Forbes Asia Best under a Billion Award - 2016.
  • 2017: Nanayam Vikatan’s Gold Phoenix Award to Mr. C C Paarthipan.
  • 2017: Financial express CFO Awards 2017 (Second Rank).
  • 2017: IPF’s industrial Excellance Award.
  • 2018: The Economic Times - Family Business of the year Award.
  • 2018: Pharmexcil Outstanding Exports Award 2018.
  • 2018: The Economic Times Award for Excellence in Business Performance.
  • 2019: Empowering India Awards 2019 in Pharmaceutical, Healthcare and Bio-Technology Segment.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.